Want to see ISRG full AI Analyst Report?
ISRG Stock Chart & Stats
$371.84
$13.91(4.12%)
At close: 4:00 PM EDT
$371.84
$13.91(4.12%)
Day’s Range― - ―
52-Week Range$328.57 - $603.88
Previous CloseN/A
Volume15.48K
Average Volume (3M)2.40M
Market Cap
$138.95B
Enterprise Value$136.97K
Total Cash (Recent Filing)$5.22B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)45.4
Beta1.19
Next Earnings
Oct 20, 2026EPS Estimate
2.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.85
Shares Outstanding353,278,050
10 Day Avg. Volume2,619,825
30 Day Avg. Volume2,395,619
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)11.34
Price to Sales (P/S)20.08
P/FCF Ratio81.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$489.95Price Target Upside31.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)10.8
Revenue Forecast (FY)$11.76B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelThe large recurring-revenue base ties sales to ongoing procedures, instrument consumption, and service contracts rather than one-time system purchases. This improves revenue visibility, supports durable cash generation, and allows installed-base growth to compound future revenue over multiple quarters.
Installed Base And Procedure GrowthProcedure growth expands recurring instrument demand and raises utilization across a growing installed base. Nearly 13,000 systems also deepen customer workflow integration, creating a durable foundation for service revenue, future placements, and adoption across additional surgical specialties.
Profitability And Financial StrengthStrong operating margins and substantial free cash flow demonstrate an established, cash-generative business model with meaningful internal funding capacity. Near-zero leverage further protects financial flexibility, enabling continued research, product development, customer support, and shareholder returns without relying heavily on debt.
Bears Say
China Market PressureChina presents a structural challenge because weaker tenders, domestic competition, and policy-led pricing pressure can constrain both system placements and economics. Da Vinci 5 is also not yet cleared there, limiting the company’s ability to use its newest platform to accelerate adoption in that market.
Extended-Use Instrument Revenue RiskThe extended-use program could improve customer economics and support procedure adoption, but it may reduce instrument-and-accessory revenue per procedure. Because recurring consumables are central to the business model, broader rollout could pressure revenue quality and margins even if procedure volumes continue growing.
Moderating Growth ProfileSlowing growth reduces the pace at which Intuitive can expand its installed base, procedures, and recurring revenue stream. A more mature growth profile also makes operating leverage and earnings expansion increasingly dependent on utilization, new indications, international execution, and successful product innovation.
Intuitive Surgical News
ISRG FAQ
What was Intuitive Surgical’s price range in the past 12 months?
Intuitive Surgical lowest stock price was $328.57 and its highest was $603.88 in the past 12 months.
What is Intuitive Surgical’s market cap?
Intuitive Surgical’s market cap is $138.95B.
When is Intuitive Surgical’s upcoming earnings report date?
Intuitive Surgical’s upcoming earnings report date is Oct 20, 2026 which is in 27 days.
How were Intuitive Surgical’s earnings last quarter?
Intuitive Surgical released its earnings results on Jul 16, 2026. The company reported $2.8 earnings per share for the quarter, beating the consensus estimate of $2.511 by $0.289.
Is Intuitive Surgical overvalued?
According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued.
Does Intuitive Surgical pay dividends?
Intuitive Surgical does not currently pay dividends.
What is Intuitive Surgical’s EPS estimate?
Intuitive Surgical’s EPS estimate is 2.64.
How many shares outstanding does Intuitive Surgical have?
Intuitive Surgical has 353,278,050 shares outstanding.
What happened to Intuitive Surgical’s price movement after its last earnings report?
Intuitive Surgical reported an EPS of $2.8 in its last earnings report, beating expectations of $2.511. Following the earnings report the stock price went down -14.145%.
Which hedge fund is a major shareholder of Intuitive Surgical?
Currently, no hedge funds are holding shares in ISRG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intuitive Surgical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$489.95 (31.76% Upside)
$489.95 (31.76% Upside)
Blogger Sentiment
Bullish
ISRG Sentiment 85%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 469.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Intuitive Surgical
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
ISRG Company Deck
ISRG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: robust revenue (+19%), strong profitability (42% non-GAAP operating margin), healthy procedure growth (total +16%) and capital placements (468 da Vinci systems), plus strong cash flow. The company also highlighted meaningful product progress (da Vinci 5 updates, SP and XiR momentum, ION adoption) and clinical evidence supporting adoption. Key risks were noted but were mostly market- and policy-driven (U.S. patient coverage dynamics, China tender and pricing pressure), some procedure-mix headwinds (bariatrics) and an unquantified impact from the extended-use instrument program. Overall, the positive metrics and growth drivers materially outweigh the challenges discussed.View all ISRG earnings summariesISRG Revenue Breakdown
67.72% U.S.
32.28% Outside of U.S
ISRG Stock 12 Month Forecast
Average Price Target
$489.95
▲(31.76% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
21.99% Mutual Funds
20.19% Other Institutional Investors
29.46% Public Companies and Individual Investors